Zacks Investment Research downgraded shares of CORONADO BIOSCI (CNDO) from OUTPERFORM to NEUTRAL on January 07, 2014, with a target price of $3.20.
Coronado Biosciences, Inc. is a biopharmaceutical company, engaged in the development of novel immunotherapy agents for cancer and inflammatory diseases. The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors. Coronado Biosciences, Inc. is based in Burlington, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CORONADO BIOSCI (CNDO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment